Eagle Pharmaceuticals Inc. (EGRX) 94.17 $EGRX
Eagle Pharmaceuticals' RTU Bivalirudin NDA Accepted for Filing
Business Wire - Thu Jul 23, 6:00AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product ("RTU bivalirudin"
has been accepted for filing by the U.S. Food and Drug Administration (FDA).
EGRX: 94.17 (+0.76)
Bears: The Gang That Couldn't Shoot Straight
at The Street - Wed Jul 22, 3:10PM CDT
They have the ammunition but they keep misfiring in the market.
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), EGRX: 94.17 (+0.76), NFLX: 110.10 (-1.40), ISRG: 557.20 (+7.32), YHOO: 39.21 (-0.03), BIDU: 207.63 (+1.89), SPY: 210.18 (-1.19), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.73 (-0.39), ARQL: 1.81 (-0.01), LLY: 86.76 (+0.38), GSK: 42.00 (-0.30), EGRX: 94.17 (+0.76), BMY: 68.24 (-1.13), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), CALA: 8.06 (-0.32), JUNO: 51.65 (-0.12), FPRX: 24.47 (-0.58), CXRX: 78.92 (+0.27)
Why Eagle Pharmaceuticals (EGRX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 7:49AM CDT
Eagle Pharmaceuticals is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective
EGRX: 94.17 (+0.76)
Will Medtronic Gain from the RF Surgical Systems Buyout? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 12:20PM CDT
Medtronic plc's (MDT) surgical solutions division is expected to get another boost with its decision to acquire RF Surgical Systems, Inc.
ICUI: 98.73 (-0.77), CMRX: 52.35 (-0.59), MDT: 76.80 (-0.02), EGRX: 94.17 (+0.76)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 11:49AM CDT
RGSE: 1.50 (-0.04), NVEE: 23.90 (-0.68), LTBR: 0.91 (-0.04), FENG: 7.43 (-0.01), STV: 3.45 (+0.01), SILC: 26.73 (-0.26), SHI: 45.14 (-0.69), CVRS: 3.84 (-0.01), EGRX: 94.17 (+0.76), HNR: 1.24 (+0.11), SYMX: 1.27 (-0.03), BUR: 1.92 (-0.10), ZINC: 8.19 (+0.35), SGNL: 1.64 (+0.04), FCVA: 4.50 (-0.29), CATB: 14.50 (+0.36), VTL: 17.08 (-0.22), ATV: 1.16 (unch), CO: 5.81 (-0.01), SIXD: 4.60 (+0.02)
Medicines Co., Eagle Pharma Up On Analyst Actions
at Investor's Business Daily - Mon Jul 06, 11:18AM CDT
Drugmakers The Medicines Company (MDCO) and Eagle Pharmaceuticals (EGRX) were both rising on bullish analyst actions Monday in the wake of Thursday's court ruling overturning the patents on Medicines' cardiovascular drug Angiomax, or bivalirudin. The...
MDCO: 34.00 (+0.16), PFE: 34.78 (-0.10), MYL: 66.56 (-1.34), SGNT: 25.53 (-0.25), TEVA: 62.51 (unch), EGRX: 94.17 (+0.76), HSP: 89.26 (+0.06)
3 Moneymaking Biotech Stocks to Consider Buying
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 05, 8:06AM CDT
Source: Flickr user stockmonkeys.com. I've been digging through the healthcare sector hunting for intriguing new ideas and I've uncovered a few biopharma companies that I think are particularly deserving of investors' attention. These three...
HZNP: 38.08 (+0.17), DEPO: 32.85 (+0.14), EGRX: 94.17 (+0.76)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
Eagle Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference
Business Wire - Tue Jun 30, 7:00AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Cantor Fitzgerald Inaugural Healthcare Conference as follows:
EGRX: 94.17 (+0.76)
Eagle Pharmaceuticals Added to Russell 2000 Index
Business Wire - Mon Jun 29, 7:00AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that it was added to the Russell 2000(R) Index and thus the broad-market Russell 3000(R) Index when the indexes reconstituted at market close on June 26, 2015.
EGRX: 94.17 (+0.76)
Game Plan For The Week - Cramer's Mad Money (6/26/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Jun 29, 6:27AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, June 26. Is there hope for Greece at all? We will know soon. Cramer discussed the game plan for the coming week. Monday Cramer expects to see Aetna (NYSE:...
AMBA: 122.99 (+0.49), MU: 18.70 (+0.70), BX: 39.73 (-1.77), IXYS: 13.73 (-0.24), HES: 59.28 (+0.28), NKE: 114.00 (-0.09), CAG: 44.00 (-0.16), AVAV: 26.67 (+0.02), M: 71.21 (-0.70), STZ: 117.56 (-1.81), LBIO: 9.47 (-0.42), EGRX: 94.17 (+0.76), AET: 112.05 (-1.83), FINL: 27.44 (-0.43), LULU: 62.00 (-0.86), VTR: 63.65 (-0.63), HUM: 184.73 (-1.37), STZ.B: 119.13 (+1.56), CI: 154.36 (+3.29), UA: 95.93 (+6.56), ANTM: 155.21 (+0.11), PAYX: 46.65 (-0.62), RELY: 12.61 (-0.05), ONCE: 69.77 (+2.62), RHT: 79.34 (-0.07), EMC: 25.97 (+0.59), GIS: 57.08 (-0.55)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jun 26, 7:09PM CDT
Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.
AMBA: 122.99 (+0.49), MU: 18.70 (+0.70), HD: 114.59 (-0.31), NKE: 114.00 (-0.09), CAG: 44.00 (-0.16), AVAV: 26.67 (+0.02), STZ: 117.56 (-1.81), PCL: 40.11 (-0.21), M: 71.21 (-0.70), LBIO: 9.47 (-0.42), KKR: 24.27 (+0.18), EGRX: 94.17 (+0.76), IDTI: 19.91 (+0.52), CSX: 30.85 (-0.72), FINL: 27.44 (-0.43), AGEN: 8.95 (-0.29), PAYX: 46.65 (-0.62), RELY: 12.61 (-0.05), ONCE: 69.77 (+2.62), RHT: 79.34 (-0.07), LOW: 67.70 (+0.26), HEES: 14.78 (-1.81), GIS: 57.08 (-0.55), CSCO: 28.01 (+0.48)
5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 33.03 (-0.86), XBI: 265.02 (-2.52), RTRX: 34.18 (-0.75), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), EXEL: 5.88 (-0.43)
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 33.03 (-0.86), XBI: 265.02 (-2.52), RTRX: 34.18 (-0.75), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), EXEL: 5.88 (-0.43)
New America's IPO Stock Winners: Fitbit, Arista
at Investor's Business Daily - Wed Jun 24, 11:51AM CDT
Health tracker Fitbit is one of two sprinting IPOs featured in IBD's The New America in the latest week. Though it gave back some gains in trading early Wednesday, it's among three companies covered that are up by more than 20% this month, and a...
ACHC: 79.70 (-0.02), FIT: 46.20 (+0.67), ANET: 84.19 (-1.01), NCLH: 59.84 (-0.05), TEVA: 62.51 (unch), EGRX: 94.17 (+0.76), AAPL: 125.16 (-0.06)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 11:40AM CDT
ACHC: 79.70 (-0.02), SGNL: 1.64 (+0.04), PRGO: 189.71 (+0.66), ESPR: 95.74 (unch), RXDX: 15.60 (-0.71), BAX: 37.97 (+0.26), UNH: 119.33 (-1.28), ONCS: 6.24 (+0.14), CVRS: 3.84 (-0.01), EGRX: 94.17 (+0.76), CASI: 1.64 (-0.07), PCRX: 62.10 (-0.03), BLRX: 2.21 (-0.05)
Eagle Pharmaceuticals' RTU Bivalirudin NDA Accepted for Filing
Business Wire - Thu Jul 23, 6:00AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product ("RTU bivalirudin"
has been accepted for filing by the U.S. Food and Drug Administration (FDA). EGRX: 94.17 (+0.76)
Bears: The Gang That Couldn't Shoot Straight
at The Street - Wed Jul 22, 3:10PM CDT
They have the ammunition but they keep misfiring in the market.
AMBA: 122.99 (+0.49), GPRO: 63.95 (+2.27), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), EGRX: 94.17 (+0.76), NFLX: 110.10 (-1.40), ISRG: 557.20 (+7.32), YHOO: 39.21 (-0.03), BIDU: 207.63 (+1.89), SPY: 210.18 (-1.19), IBM: 161.73 (+1.38), CMG: 725.94 (+0.12), GOOGL: 674.73 (-20.37), MSFT: 46.11 (+0.57), AAPL: 125.16 (-0.06)
Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx3h4b/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - Amphera BV - Applied Research using OMIC Sciences, S.L. - arGEN-X BV - ArQule, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - CanBas Co., Ltd. - Concordia Healthcare Corp. - CritiTech, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lx3h4b/malignant
ADRO: 28.73 (-0.39), ARQL: 1.81 (-0.01), LLY: 86.76 (+0.38), GSK: 42.00 (-0.30), EGRX: 94.17 (+0.76), BMY: 68.24 (-1.13), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), CALA: 8.06 (-0.32), JUNO: 51.65 (-0.12), FPRX: 24.47 (-0.58), CXRX: 78.92 (+0.27)
Why Eagle Pharmaceuticals (EGRX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 7:49AM CDT
Eagle Pharmaceuticals is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective
EGRX: 94.17 (+0.76)
Will Medtronic Gain from the RF Surgical Systems Buyout? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 12:20PM CDT
Medtronic plc's (MDT) surgical solutions division is expected to get another boost with its decision to acquire RF Surgical Systems, Inc.
ICUI: 98.73 (-0.77), CMRX: 52.35 (-0.59), MDT: 76.80 (-0.02), EGRX: 94.17 (+0.76)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 11:49AM CDT
RGSE: 1.50 (-0.04), NVEE: 23.90 (-0.68), LTBR: 0.91 (-0.04), FENG: 7.43 (-0.01), STV: 3.45 (+0.01), SILC: 26.73 (-0.26), SHI: 45.14 (-0.69), CVRS: 3.84 (-0.01), EGRX: 94.17 (+0.76), HNR: 1.24 (+0.11), SYMX: 1.27 (-0.03), BUR: 1.92 (-0.10), ZINC: 8.19 (+0.35), SGNL: 1.64 (+0.04), FCVA: 4.50 (-0.29), CATB: 14.50 (+0.36), VTL: 17.08 (-0.22), ATV: 1.16 (unch), CO: 5.81 (-0.01), SIXD: 4.60 (+0.02)
Medicines Co., Eagle Pharma Up On Analyst Actions
at Investor's Business Daily - Mon Jul 06, 11:18AM CDT
Drugmakers The Medicines Company (MDCO) and Eagle Pharmaceuticals (EGRX) were both rising on bullish analyst actions Monday in the wake of Thursday's court ruling overturning the patents on Medicines' cardiovascular drug Angiomax, or bivalirudin. The...
MDCO: 34.00 (+0.16), PFE: 34.78 (-0.10), MYL: 66.56 (-1.34), SGNT: 25.53 (-0.25), TEVA: 62.51 (unch), EGRX: 94.17 (+0.76), HSP: 89.26 (+0.06)
3 Moneymaking Biotech Stocks to Consider Buying
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 05, 8:06AM CDT
Source: Flickr user stockmonkeys.com. I've been digging through the healthcare sector hunting for intriguing new ideas and I've uncovered a few biopharma companies that I think are particularly deserving of investors' attention. These three...
HZNP: 38.08 (+0.17), DEPO: 32.85 (+0.14), EGRX: 94.17 (+0.76)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.42 (-0.14), NFLX: 110.10 (-1.40), BLUE: 163.54 (+1.54), AMZN: 482.18 (-6.09), TSLA: 267.20 (-0.67), KITE: 71.68 (-0.43), LBIO: 9.47 (-0.42), JUNO: 51.65 (-0.12), EGRX: 94.17 (+0.76)
Eagle Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference
Business Wire - Tue Jun 30, 7:00AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Cantor Fitzgerald Inaugural Healthcare Conference as follows:
EGRX: 94.17 (+0.76)
Eagle Pharmaceuticals Added to Russell 2000 Index
Business Wire - Mon Jun 29, 7:00AM CDT
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that it was added to the Russell 2000(R) Index and thus the broad-market Russell 3000(R) Index when the indexes reconstituted at market close on June 26, 2015.
EGRX: 94.17 (+0.76)
Game Plan For The Week - Cramer's Mad Money (6/26/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Jun 29, 6:27AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, June 26. Is there hope for Greece at all? We will know soon. Cramer discussed the game plan for the coming week. Monday Cramer expects to see Aetna (NYSE:...
AMBA: 122.99 (+0.49), MU: 18.70 (+0.70), BX: 39.73 (-1.77), IXYS: 13.73 (-0.24), HES: 59.28 (+0.28), NKE: 114.00 (-0.09), CAG: 44.00 (-0.16), AVAV: 26.67 (+0.02), M: 71.21 (-0.70), STZ: 117.56 (-1.81), LBIO: 9.47 (-0.42), EGRX: 94.17 (+0.76), AET: 112.05 (-1.83), FINL: 27.44 (-0.43), LULU: 62.00 (-0.86), VTR: 63.65 (-0.63), HUM: 184.73 (-1.37), STZ.B: 119.13 (+1.56), CI: 154.36 (+3.29), UA: 95.93 (+6.56), ANTM: 155.21 (+0.11), PAYX: 46.65 (-0.62), RELY: 12.61 (-0.05), ONCE: 69.77 (+2.62), RHT: 79.34 (-0.07), EMC: 25.97 (+0.59), GIS: 57.08 (-0.55)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jun 26, 7:09PM CDT
Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.
AMBA: 122.99 (+0.49), MU: 18.70 (+0.70), HD: 114.59 (-0.31), NKE: 114.00 (-0.09), CAG: 44.00 (-0.16), AVAV: 26.67 (+0.02), STZ: 117.56 (-1.81), PCL: 40.11 (-0.21), M: 71.21 (-0.70), LBIO: 9.47 (-0.42), KKR: 24.27 (+0.18), EGRX: 94.17 (+0.76), IDTI: 19.91 (+0.52), CSX: 30.85 (-0.72), FINL: 27.44 (-0.43), AGEN: 8.95 (-0.29), PAYX: 46.65 (-0.62), RELY: 12.61 (-0.05), ONCE: 69.77 (+2.62), RHT: 79.34 (-0.07), LOW: 67.70 (+0.26), HEES: 14.78 (-1.81), GIS: 57.08 (-0.55), CSCO: 28.01 (+0.48)
5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 33.03 (-0.86), XBI: 265.02 (-2.52), RTRX: 34.18 (-0.75), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), EXEL: 5.88 (-0.43)
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 33.03 (-0.86), XBI: 265.02 (-2.52), RTRX: 34.18 (-0.75), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), EXEL: 5.88 (-0.43)
New America's IPO Stock Winners: Fitbit, Arista
at Investor's Business Daily - Wed Jun 24, 11:51AM CDT
Health tracker Fitbit is one of two sprinting IPOs featured in IBD's The New America in the latest week. Though it gave back some gains in trading early Wednesday, it's among three companies covered that are up by more than 20% this month, and a...
ACHC: 79.70 (-0.02), FIT: 46.20 (+0.67), ANET: 84.19 (-1.01), NCLH: 59.84 (-0.05), TEVA: 62.51 (unch), EGRX: 94.17 (+0.76), AAPL: 125.16 (-0.06)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 11:40AM CDT
ACHC: 79.70 (-0.02), SGNL: 1.64 (+0.04), PRGO: 189.71 (+0.66), ESPR: 95.74 (unch), RXDX: 15.60 (-0.71), BAX: 37.97 (+0.26), UNH: 119.33 (-1.28), ONCS: 6.24 (+0.14), CVRS: 3.84 (-0.01), EGRX: 94.17 (+0.76), CASI: 1.64 (-0.07), PCRX: 62.10 (-0.03), BLRX: 2.21 (-0.05)
